Skip to main content
Premium Trial:

Request an Annual Quote

Applera Expands Access to Credit to $200M and Higher

NEW YORK, April 21 (GenomeWeb News) - Applera has entered into a five-year $200 million unsecured credit agreement with a group of lenders, according to an SEC document the company filed yesterday.


The new agreement replaces an existing $50 million revolving credit agreement that was scheduled to mature on April 20, the company said in the filing. The new credit facility, which ABI will use for general corporate purposes, can increase to $250 million as long as the company maintains a consolidated net worth of at least $900 million and a debt-to-capitalization ratio of no more than .50 to 1.00, according to the document.


Applera, which will report its financials next week, is currently debt-free and holds some $650 million in cash.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.